

# PRODUCT INFORMATION



**BI-3802**

Item No. 41731

**CAS Registry No.:** 2166387-65-9

**Formal Name:** *rel*-2-[[6-[[5-chloro-2-[(3*R*,5*S*)-3,5-dimethyl-1-piperidinyl]-4-pyrimidinyl]amino]-1,2-dihydro-1-methyl-2-oxo-3-quinolinyl]oxy]-*N*-methyl-acetamide

**MF:** C<sub>24</sub>H<sub>29</sub>ClN<sub>6</sub>O<sub>3</sub>


**FW:** 485.0

**Purity:** ≥95%

**Supplied as:** A solid

**Storage:** -20°C

**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

## Laboratory Procedures

BI-3802 is supplied as a solid. A stock solution may be made by dissolving the BI-3802 in the solvent of choice, which should be purged with an inert gas. BI-3802 is sparingly soluble (1-10 mg/ml) in DMSO and slightly soluble (0.1-1 mg/ml) in acetonitrile.

## Description

BI-3802 is a degrader of Bcl-6 with a half-maximal degradation concentration (DC<sub>50</sub>) value of 20 nM in SU-DHL-4 B cell lymphoma cells.<sup>1</sup> It binds to Bcl-6 in a cell-free assay and inhibits the interaction of Bcl-6 with nuclear receptor co-repressor 1 (NCOR1) in a reporter assay (IC<sub>50</sub>s = ≤3 and 43 nM, respectively). BI-3802 induces Bcl-6 polymerization, as well as SIAH1-dependent ubiquitination of Bcl-6, in cell-free assays.<sup>2</sup> It induces expression of the Bcl-6 target genes *PTPN6* and *RAPGEF1* in SU-DHL-4 cells in a concentration- and time-dependent manner.<sup>1</sup> BI-3802 enhances decreases in tumor volume and weight induced by the c-Abl, Bcr-Abl, PDGFR, and c-Kit inhibitor imatinib (Item No. 13139) in a GIST-T1 gastrointestinal stromal tumor mouse xenograft model.<sup>3</sup>

## References

1. Kerres, N., Steurer, S., Schlager, S., *et al.* Chemically induced degradation of the oncogenic transcription factor BCL6. *Cell. Rep.* **20**(12), 2860-2875 (2017).
2. Stabicki, M., Yoon, H., Koepfel, J., *et al.* Small-molecule-induced polymerization triggers degradation of BCL6. *Nature* **588**(7836), 164-168 (2020).
3. Zeng, X., Zhao, F., Jia, J., *et al.* Targeting BCL6 in gastrointestinal stromal tumor promotes p53-mediated apoptosis to enhance the antitumor activity of imatinib. *Cancer Res.* **83**(21), 3624-3635 (2023).

### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 09/03/2024

## CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
[WWW.CAYMANCHEM.COM](http://WWW.CAYMANCHEM.COM)